2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2082

Identification of Major Clinical Characteristics and Linear Correlations Among DAS28, HAQ and Morning Stiffness Time Using Smart System of Disease Management (SSDM)
Abstract Number: 2083

Comparing the Electronic Patient Reported Outcome (ePro) Tool Versus the Paper Reported Outcome (pPro) Tool in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Abstract Number: 2084

Effects of a Web-Based Patient Decision Aid on Biologics for Rheumatoid Arthritis: A Proof-of-Concept Study
Abstract Number: 2085

Minding the Gap: the Use of Nurse Practitioners and Physician Assistants in U.S. Rheumatology Practice to Affect Rheumatology Workforce Shortages
Abstract Number: 2086

Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients
Abstract Number: 2087

A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome
Abstract Number: 2088

Rituximab Use in Pediatric Lupus Anticoagulant Hypoprothrombinemia Syndrome – Report of Three Cases and Review of the Literature
Abstract Number: 2089

Deviation of T and B Cell Subset and Its Association with Single Nucleotide Polymorphisms in Patients with Antiphospholipid Syndrome
Abstract Number: 2090

Investigating the Genetic Variations of Antiphospholipid Syndrome By High-Throughput Exome Sequencing
Abstract Number: 2091

Antiphospholipid Syndrome Patients’ Time within Therapeutic Range of International Normalized Ratio (INR)
Abstract Number: 2092

Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.
Abstract Number: 2093

Association of Conventional Risk Factors and Antiphospholipid Antibodies to Thrombosis in Patients with Autoimmune Diseases: Lessons Learned from a Year-Long Systematic Assessment
Abstract Number: 2094

Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Abstract Number: 2095

Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome
Abstract Number: 2096

Venous Antiphospholipid Syndrome: Is the Unprovoked Nature of the 1st Thrombosis Associated with Clinical or Biological Features?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].